Strategic Wealth Investment Group LLC Buys 4,263 Shares of Danaher Co. (NYSE:DHR)

Strategic Wealth Investment Group LLC grew its position in Danaher Co. (NYSE:DHR) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,176 shares of the conglomerate’s stock after purchasing an additional 4,263 shares during the quarter. Strategic Wealth Investment Group LLC’s holdings in Danaher were worth $9,452,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the 3rd quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on DHR shares. Raymond James dropped their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. JPMorgan Chase & Co. cut their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday. KeyCorp raised their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group cut their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, Jefferies Financial Group decreased their target price on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Stock Down 0.3 %

Shares of NYSE DHR opened at $223.16 on Friday. Danaher Co. has a 52-week low of $221.34 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The business has a fifty day moving average of $235.89 and a two-hundred day moving average of $253.45. The stock has a market cap of $161.19 billion, a PE ratio of 42.27, a PEG ratio of 4.22 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period last year, the firm earned $2.09 EPS. As a group, equities research analysts expect that Danaher Co. will post 8.15 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s payout ratio is 20.45%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.